Vaccines are being touted as taking seven to ten years to develop. But you shouldn't be worried that COVID vaccines only took less than a year.
A woman walks by graffiti reading ‘No vaccine, No tracking, No COVID’, in Montréal on Aug. 16, 2020.
THE CANADIAN PRESS/Graham Hughes
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Early data shows that vaccines work for older people who are more at risk of severe COVID-19.
Asking these four questions can help us identify good news when we see it, be more critical of news reports, or delay our judgement until we have more information.
The recent vaccine trial results certainly look impressive, but here's how to fully interrogate what they mean.
Any COVID-19 vaccine is likely to be given first to higher risk groups before it is given to children. But we still need vaccines that are safe and effective for them too.
Pregnant women are routinely excluded from clinical trials for drugs and vaccines.
Pregnant women are at increased risk for serious COVID-19 complications and should be a high-priority group for vaccination. Excluding them from vaccine trials puts them and their offspring at risk.
There are many scientific and ethical challenges ahead. But these types of trials have helped in the development of vaccines against a few diseases. Could they do the same for COVID-19?
Australia's contribution to the global COVAX initiative helps secure future vaccines. Here's the full field of candidates.
A lab technician holds a vial of a COVID-19 vaccine candidate during testing at the Chula Vaccine Research Center, run by Chulalongkorn University in Bangkok, Thailand on May 25, 2020.
(AP Photo/Sakchai Lalit)
Will a vaccine for COVID-19 be safe? Animal testing, human clinical trials and post-approval surveillance give us good grounds to believe that a future approved vaccine will work and be safe.
Stoppages of clinical trials are a normal part of the testing process, and show that patient safety is being taken seriously.
A researcher working on the University of Oxford/AstraZeneca vaccine in Buenos Aires.
The COVID-19 vaccine is in the final stages of testing – meaning we should know whether it's effective before the end of the year.
There is a lack of good clinical research on the advantages of blue-light filtering lenses.
Some health products haven't been tested for the benefits that they claim to produce. Blue-light blocking lenses are promoted as helping sleep cycles, but there is no evidence to support this.
Towfiqu ahamed barbhuiya/Shutterstock
Most medical treatments don't work according to the best evidence.
Julian Smith/AAP Image
The head lice drug ivermectin is being touted as a coronavirus killer. But studies suggest it would need to be taken in mega-doses far higher than those currently used, with unknown side-effects.
On Aug. 11, Russian President Vladimir Putin announced that a coronavirus vaccine developed in the country has been registered for use.
Russian Health Ministry/Handout/Anadolu Agency via Getty Images
As Russia fast tracks a coronavirus vaccine, scientists worry about skipped safety checks – and the potential fallout for trust in vaccines if something ends up going wrong.
As antimicrobial resistance increases, the options for treating serious infections dwindle. Doctors need reliable information about which treatments to try out.
Further tests are needed but a trial showed that, when compared against placebo treatment, those given the drug had a 79% lower risk of developing severe disease.
The race is on to develop a vaccine for the COVID-19 coronavirus. Australian researchers are leading several major clinical trials that might help bring an end to the deadly disease.
Researchers are central to any country’s science preparedness, especially in the face of pandemics.
Menna Hossam/picture alliance via Getty Images
Investments are starting to help grow the African continent's science preparedness.